Search
Shanghai RAAS Blood Products Co., Ltd. has recently announced that its application for a new clinical trial indication of "SR604 Injection" for the "Prevention and Treatment of Bleeding Episodes in Patients with Von Willebrand Disease" has been granted approval by the National Medical Products Administration. SR604 Injection is a humanized monoclonal antibody preparation that exhibits a high affinity for human activated protein C, specifically targeting and inhibiting its anticoagulation function. Currently, there are no products on the global market that share this drug's target, nor are there any approved antibody drugs specifically for the prevention and treatment of von Willebrand disease. Should this application prove successful, it is anticipated to bridge a significant gap in this therapeutic landscape.
-
C114 Communication Network -
Communication Home
